With 0.74 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.46 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.379 whereas the lowest price it dropped to was $0.3351. The 52-week range on IGC shows that it touched its highest point at $0.91 and its lowest point at $0.25 during that stretch. It currently has a 1-year price target of $4.00. Beta for the stock currently stands at 1.30.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of IGC was down-trending over the past week, with a drop of -8.43%, but this was up by 13.71% over a month. Three-month performance surged to 10.43% while six-month performance fell -19.26%. The stock gained 28.04% in the past year, while it has gained 35.31% so far this year. A look at the trailing 12-month EPS for IGC yields -0.19 with Next year EPS estimates of -0.12. For the next quarter, that number is -0.03. This implies an EPS growth rate of 50.00% for this year and -9.09% for next year.
Float and Shares Shorts:
At present, 76.64 million IGC shares are outstanding with a float of 53.25 million shares on hand for trading. On 2024-10-31, short shares totaled 1.22 million, which was 162.0 higher than short shares on 1727654400. In addition to Mr. Ram Mukunda as the firm’s President, CEO & Director, Ms. Claudia Grimaldi serves as its VP, Principal Financial Officer, Chief Compliance Officer & Non-Independent Director.
Institutional Ownership:
Through their ownership of 0.22001 of IGC’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, IGC reported revenue of $412000.0 and operating income of -$1760000.0. The EBITDA in the recently reported quarter was -$1615000.0 and diluted EPS was -$0.02.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for IGC since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With IGC analysts setting a high price target of 4.0 and a low target of 3.5, the average target price over the next 12 months is 3.75. Based on these targets, IGC could surge 952.63% to reach the target high and rise by 821.05% to reach the target low. Reaching the average price target will result in a growth of 886.84% from current levels.
Analysts have provided yearly estimates in a range of -$0.21718 being high and -$0.22282 being low. For IGC, this leads to a yearly average estimate of -$0.22. Based on analyst estimates, the high estimate for the next quarter is -$0.03 and the low estimate is -$0.03. The average estimate for the next quarter is thus -$0.03.
